Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus FORTAZ.
ANCEF IN PLASTIC CONTAINER vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic